ArticleStem cell research & therapy2026
Immunomodulatory effect of mesenchymal stromal cell overexpressing HLA-G1 in cell-based therapy for myocardial infarction.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOur previous study revealed that intravenous administration of mesenchymal stromal cells (MSCs) increases local cell engraftment and improves heart function. This study aims to investigate whether MSCs overexpressing HLA-G1 have further increased local transplanted cells engraftment and improved heart function.
methodsThe mice were intravenously administered saline or human umbilical cord blood-derived MSCs (hUCB-MSCs) 7 days before myocardial infarction (MI) induction. Then, the MI mouse model was established by ligating the left anterior descending coronary artery. The mice were then subjected to intramyocardial transplantation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 30 min after MI induction. Echocardiographic analysis was carried out to assess heart function. Furthermore, in vivo fluorescent imaging analysis was performed to analyze cell engraftment. Moreover, flow cytometry of splenic regulatory T cells (Tregs) and natural killer (NK) cells was conducted to evaluate the immunomodulatory effect of hUCB-MSCs.
resultsThe results showed that systemic intravenous administration of hUCB-MSCs substantially enhanced Tregs, decreased NK cells, and increased intramyocardially transplanted hiPSC-CMs' engraftment, thus improving heart function. Compared with hUCB-MSCs, HLA-G1 overexpressing hUCB-MSCs reduced systemic NK cells (7.13 ± 0.19% vs. 9.12 ± 0.06%, p < 0.05), increased Tregs (5.03 ± 0.17% vs. 3.36 ± 0.05%, p < 0.05), improved cell engraftment (Radiant efficiency: 3.01 ± 0.36 × 10
conclusionsThis study showed that systemic intravenous administration of HLA-G1 overexpressing hUCB-MSCs modulated immune response and increased transplanted hiPSC-CMs' engraftment to improve heart function following AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.